Vertex PharmaNASDAQ:VRTX is on a verge of a breakout. AMEX:XPH is also staging a recovery, but still trading below key levels. For now, the focus in on a NASDAQ:VRTX look position.
Key stats
About SPDR S&P Pharmaceuticals ETF
Expense ratio
0.35%
Home page
Inception date
Jun 19, 2006
ISIN
US78464A7220
XPH offers equal-weighted exposure to a narrow selection of US pharmaceutical companies, stretching across all market caps. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. The fund also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. Overall, XPH is a solid way to capture a less concentrated version of the pharma market. The index is rebalanced quarterly.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
XPH | Pharmaceuticals to Outperform- Price is breaking minor falling wedge pattern on strong volume
- Pharmaceutical stocks have lagged the broader market in the past year and have not been so inexpensive relative to the S&P 500 in at least 20 years
- As the healthcare sector is starting to out perform the overall market, I have be
ETFs potential BUYS -XPH-EIDO-EUO-XBI-BIBFor Monday’s open, 5 ETF's are potential buys under my rules for Pullback Strategy. This strategy identifies oversold ETFs and takes advantage of the tendency for prices to revert to the mean in the short term.
The ETFs set up as potential buys for Monday are listed in the table below:
XPH -SPDR S&P
See all ideas